/home/corante/public_html/pipeline/ en-us derek-lowe@sbcglobal.net 2009-11-06T08:55:48-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2009/11/06/thoughts_on_what_used_to_be_scheringplough.php So what are we up to now, Day Three of Greater Merck? The merger with Schering-Plough went through earlier this week, and you won't get any more numbers by searching the stock tickers for SGP. I find that weird, since... 74127@/home/corante/public_html/pipeline/ Business and Markets 2009-11-06T08:55:48-05:00 http://pipeline.corante.com/archives/2009/11/03/jj_raises_the_ax.php Johnson & Johnson says that it could be cutting up to 8,000 jobs. This has been in the wind for a while, but I haven't had any reports yet of what it's doing on the ground to the research sites.... 74122@/home/corante/public_html/pipeline/ Business and Markets 2009-11-03T10:56:48-05:00 http://pipeline.corante.com/archives/2009/11/02/in_which_you_get_to_hear_the_phrase_hatchwaxman_again.php There's a constant running battle in the drug industry between the two kinds of pharmaceutical companies: the ones who discover the drugs first, and the ones who sell the drugs cheaply after the patents have expired. It surprises me still... 74120@/home/corante/public_html/pipeline/ Business and Markets 2009-11-02T07:45:21-05:00 http://pipeline.corante.com/archives/2009/10/30/fifty_years_of_scientific_history_for_you.php Here's a most interesting graph from the latest issue of Nature Reviews Drug Discovery. It's from an article on trying to discern trends from broad-scale literature analysis, and it's worth a separate blog post of its own (coming shortly). But... 74118@/home/corante/public_html/pipeline/ Drug Industry History 2009-10-30T08:50:16-05:00 http://pipeline.corante.com/archives/2009/10/29/the_best_ones_arent_over_here_any_more.php Here's one to get your attention: there's been a lot of arguing (on this blog and others) about the continual talk of shortages of scientists and engineers. That's a little hard to take for the number of people who've been... 74117@/home/corante/public_html/pipeline/ Business and Markets 2009-10-29T12:13:59-05:00 http://pipeline.corante.com/archives/2009/10/28/you_mean_you_dont_have_to_buy_them.php Johnson & Johnson's CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions. And right now, that strategy is. . .not to make acquisitions. They see partnerships as making a lot more sense: “The cost... 74114@/home/corante/public_html/pipeline/ Business and Markets 2009-10-28T06:30:47-05:00 http://pipeline.corante.com/archives/2009/10/22/red_flags_in_biotech.php Xconomy has a useful two-part interview with Christopher Henney, who helped to found Icos, Dendreon, and Immunex. The part I found most interesting, naturally, was the section entitled "Five Red Flags of Biotech". (Note to the Xconony folks - the... 74108@/home/corante/public_html/pipeline/ Business and Markets 2009-10-22T06:32:21-05:00 http://pipeline.corante.com/archives/2009/10/21/pfizers_people.php I wanted to highlight a comment that showed up recently in the latest Pfizer post: I would just like to point out that there is often mention of Pfizer as being a poorly productive R&D outfit on this blog, but... 74106@/home/corante/public_html/pipeline/ Business and Markets 2009-10-21T10:24:26-05:00 http://pipeline.corante.com/archives/2009/10/21/o_brave_new_world_that_has_such_companies_int.php Steve Usdin at BioCentury sent along a reprint of the newsletter's annual "Back to School" issue from last month (available for open access here) in response to my note about "micropharma" the other day. And it's clear that he's been... 74105@/home/corante/public_html/pipeline/ Business and Markets 2009-10-21T07:16:48-05:00 http://pipeline.corante.com/archives/2009/10/20/what_pfizer_will_look_like_in_a_year.php The Wall Street Journal's Health Blog got a chance to ask the higher-ups at Pfizer what their R&D will look like a year from now. Their (understandably) not too-in-depth answers are here: Decentralized research units, with some functions run company-wide,... 74104@/home/corante/public_html/pipeline/ Business and Markets 2009-10-20T06:52:12-05:00 http://pipeline.corante.com/archives/2009/10/19/short_topics_from_all_over.php (1) Bnet Pharma on "How Not to Write a Pharma Press Release". Privately held Epeius is sending out bulletins loaded with phrases like "more stunning results" and "Epeius Biotechnologies draws the sword of targeted gene delivery from the stone of... 74102@/home/corante/public_html/pipeline/ Business and Markets 2009-10-19T07:56:18-05:00 http://pipeline.corante.com/archives/2009/10/16/day_one_at_pfizer.php I've heard from several sources that today is what they're calling "Day One" at Pfizer. The merger with Wyeth is now official, and word is going to start going out on which sites will stay, which will close, and who... 74101@/home/corante/public_html/pipeline/ Business and Markets 2009-10-16T09:18:55-05:00 http://pipeline.corante.com/archives/2009/09/28/which_pfizer_wyeth_sites_will_close.php I have no solid information on this question myself, but Eric Milgram over at Pharmaconduct is trying a wisdom-of-crowds approach. He's got a survey up of which sites people think will close, and it'll be interested to see how well... 74078@/home/corante/public_html/pipeline/ Business and Markets 2009-09-28T10:21:18-05:00 http://pipeline.corante.com/archives/2009/09/17/the_drug_business_a_turbulent_future.php One of this blog's regular correspondents has just been attending a chemistry outsourcing conference (program here), and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren's a product of the Sharpless lab,... 74064@/home/corante/public_html/pipeline/ Business and Markets 2009-09-17T06:25:47-05:00 http://pipeline.corante.com/archives/2009/09/15/lilly_shrinks.php The latest re-org announcement is from Eli Lilly. The company is getting braced for the Zyprexa patent expiration (and the possibility that Prasugrel and others won't be able to make up for as much lost revenue as they thought). Their... 74062@/home/corante/public_html/pipeline/ Business and Markets 2009-09-15T09:51:06-05:00